TitleRobust Genome Engineering in Primary Human T Cells using CRISPR/Cas9 Ribonucleoproteins
OwnerUniversity of California
Description

UCSF researchers have developed a powerful Cas9 RNP-based technology that uses purified Cas9 ribonucleoproteins (RNP) for successful and efficient genome editing in primary human CD4+ T cells. Cas9 protein pre-complexed with a single guide RNA (sgRNA) is introduced as an RNP into human T cells by transient electroporation. The active complexes enabled the first successful Cas9-mediated homology directed repair (HDR) in primary human T cells. Cas9 RNPs have allowed generation of ‘knock-in’ primary human T cells with targeted genetic replacement of specific nucleotides, which was previously unattainable.


Application

1) Unprecedented flexibility to ‘knock-out’ and ‘knock-in’ specific genetic elements in engineered T cells for cancer immunotherapy

2) New opportunity for therapeutic gene correction for primary immune deficiencies, treatment of infections and autoimmune diseases

3) Diverse research applications examining the function of coding and non-coding genetic variation in human immune regulation

 

Stage of Development

Proof of principle

Related Materials

 

  • Not available at this time

Data Availability

In vitro human data

 

Date:01-08-2017
Applicants:University of California
Access to additional documentation:Please inquire
Case Ref:UC Case 2015-118-0
Application number:please inquire
Support from inventors:Please inquire
Industry:Healthcare
Meta information:
Meta title:
Please fill out the form and press 'send'
Contact Seller
Please provide your contact information below.

Use this form to contact the IP-owner - you should provide an email of your choice for contact. Indicate your interest/reason for the contact.
Disclaimer: Licentix do not guarantee that message sent using this form will be read by the recipient. Please contact us if you are not recieving any response.